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A Genome-wide study of blood
pressure in African Americans
accounting for gene-smoking
interaction
Jacquelyn Y. Taylor1, Karen Schwander2, Sharon L. R. Kardia3 & Donna Arnett4, Jingjing Liang5
Steven C. Hunt6, D.C. Rao2 & Yan V. Sun7,8
Cigarette smoking has been shown to be a health hazard. In addition to being considered a
negative lifestyle behavior, studies have shown that cigarette smoking has been linked to genetic
underpinnings of hypertension. Because African Americans have the highest incidence and prevalence
of hypertension, we examined the joint effect of genetics and cigarette smoking on health among this
understudied population. The sample included African Americans from the genome wide association
studies of HyperGEN (N = 1083, discovery sample) and GENOA (N = 1427, replication sample), both
part of the FBPP. Results suggested that 2 SNPs located on chromosomes 14 (NEDD8; rs11158609;
raw p = 9.80 × 10−9, genomic control-adjusted p = 2.09 × 10−7) and 17 (TTYH2; rs8078051; raw
p = 6.28 × 10−8, genomic control-adjusted p = 9.65 × 10−7) were associated with SBP including the
genetic interaction with cigarette smoking. These two SNPs were not associated with SBP in a main
genetic effect only model. This study advances knowledge in the area of main and joint effects of
genetics and cigarette smoking on hypertension among African Americans and offers a model to the
reader for assessing these risks. More research is required to determine how these genes play a role in
expression of hypertension.
It has been widely accepted that environmental factors such as lifestyle behaviors that include excess tobacco usage
can be hazardous to one’s health1,2. There is evidence that cigarette smoking is a risk factor for development of
chronic diseases such as hypertension, stroke, chronic obstructive pulmonary disease, and end organ damage1–4.
Both behavioral aspects of dependence of tobacco usage3,4 and genetic underpinnings5,6 have been independently
noted in the literature to mediate and/or modulate overall health.
The term gene-environment (G ×  E) interaction is used to define the biological or statistical interplay between
genetic and environmental factors7. The statistical interactions, defined as the non-additive effects of the gene and
environment, have been widely investigated in genetic epidemiological studies. Using high-throughput genotyping
technologies, it is possible to conduct genome-wide studies accounting for G ×  E interaction to identify genetic
and environmental factors jointly influence a disease trait. However, challenges in study design and analytical
methods remains in the GWAS era after decades of research in genetic epidemiology7,8. In simulation studies, a
joint test for main genetic effect and interaction effects was recently proposed and showed improved power with
the presence of moderate interaction effect or the interaction effect in the opposite direction of the main effect9.
Manning et al. applied the joint test in a genome-wide study, and identified joint effects of SNP and SNP-BMI
interaction related to fasting glycemic traits10.
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HyperGEN

GENOA
Male (n =  438)
Mean ±  SD

Female
(n =  989)
Mean ±  SD

58.64 ±  9.96

59.84 ±  9.58

58.12 ±  10.07

31.09 ±  6.65

28.47 ±  4.96

32.22 ±  6.95

103.36 ±  16.74

100.66 ±  12.73

104.52 ±  18.07

117.77 ±  16.90

113.26 ±  14.67

105.72 ±  11.00

116.49 ±  14.87

0.88 ±  0.08

0.91 ±  0.08

0.95 ±  0.05

0.89 ±  0.08

128.67 ±  22.69

136.41 ±  22.96

135.32 ±  22.20

136.88 ±  23.27

Variable

Pooled
(n =  1083)
Mean ±  SD

Male (n =  354)
Mean ±  SD

Female
(n =  729)
Mean ±  SD

Age (year)

44.07 ±  13.38

42.86 ±  13.64

44.66 ±  13.21

BMI (kg/m2)

32.57 ±  8.19

29.82 ±  6.55

33.91 ±  8.57

Waist circumference (cm)

102.88 ±  18.96

100.17 ±  17.48

104.18 ±  19.51

Hip circumference (cm)

114.68 ±  16.44

108.31 ±  13.39

0.89 ±  0.08

0.92 ±  0.08

129.08 ±  22.24

129.93 ±  21.29

Waist-hip-ratio
SBP (mmHg)

Pooled
(n =  1427)
Mean ±  SD

DBP (mmHg)

73.90 ±  11.73

76.50 ±  12.61

72.64 ±  11.08

77.49 ±  12.25

79.22 ±  12.50

76.75 ±  12.08

Adjusted SBP (mmHg)

142.84 ±  28.85

142.06 ±  27.91

143.22 ±  29.31

142.72 ±  24.39

140.90 ±  23.61

143.50 ±  24.68

Adjusted DBP (mmHg)

82.77 ±  15.29

84.26 ±  16.61

82.05 ±  14.57

80.65 ±  12.55

82.01 ±  12.72

80.06 ±  12.43

Cholesterol (mg/dL)

191.53 ±  41.58

186.29 ±  40.32

194.09 ±  41.97

204.97 ±  46.11

198.11 ±  47.86

207.91 ±  45.04

HDL cholesterol (mg/dL)

53.27 ±  15.31

48.73 ±  13.97

55.49 ±  15.45

55.46 ±  18.01

49.50 ±  17.52

58.01 ±  17.61

Triglycerides (mg/dL)

107.03 ±  85.30

113.34 ±  89.01

103.94 ±  83.31

146.69 ±  90.32

150.59 ±  116.75

145.01 ±  76.25

Ever Smoker

48.5%

63.6%

41.2%

43.3%

67.7%

32.9%

Current Smoker

28.5%

38.1%

23.9%

19.5%

28.8%

15.6%

Diabetes

19.4%

15.8%

21.1%

22.3%

19.0%

23.8%

Hypertension

68.7%

62.4%

71.8%

73.8%

69.8%

75.5%

Table 1. Descriptive statistics of the HyperGEN sample.

Research in the area of genetics of cigarette smoking has expanded to include national consortiums11,12 and
work groups for conducting genome wide association studies (GWAS) in this area13,14 . However, none have considered the gene-environment interaction effects of cigarette smoking on predicting high blood pressure in an
African American sample. We propose to examine African Americans participants in the Hypertension Genetic
Epidemiology Network (HyperGEN) study, and replicate the association in African American participants from
the Genetic Epidemiology Network of Arteriopathy (GENOA) study, two large epidemiological studies of hypertension genetics. We have selected African Americans as the target of our investigation because they have the
highest incidence and prevalence of hypertension than any other ethnic group in the United States. Because African
Americans are at greatest risk for development of hypertension1, it is important to consider the gene-environment
interactions that may contribute to this disparity.
GWAS have paved the way for the examination of a multitude of single nucleotide polymorphisms (SNPs)
that may contribute to development of various diseases such as hypertension15–20. The Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) Consortium identified genome-wide significant loci (p
value <  5 ×  10−8) for hypertension and systolic and diastolic blood pressure, respectively15. When combined with
the Global Blood Pressure Genetics (GlobalBPGen) Consortium data16, the joint analysis of results identified 11
genome-wide significant associations with hypertension, systolic or diastolic blood pressure from 8 independent
loci. Advancements made by GWAS aid in understanding the genetic underpinnings of blood pressure regulation
and potential mechanistic interactions. The results of these consortium studies highlight the association between
common variants, blood pressure, and hypertension and suggest potential target areas for cardiovascular disease
prevention, intervention, and treatments. GWAS efforts have also found moderate associations with SNPs on
genes found to be significant for high blood pressure among Europeans, but continued work must be done among
African American populations20,21. The International Consortium for Blood Pressure Genome-wide Association
Studies (ICBP-GWAS) found that blood pressure among African Americans is a trait with genetic foundations
similar to those of European ancestry but with significant intricacy20. In a recent blood pressure GWAS of 29,378
individuals with African ancestry, five loci were genome-wide significant using transethnic analyses22. We propose
to advance knowledge in this area of joint effect of genetics and cigarette smoking on blood pressure among African
Americans. We offer a model to the reader for assessing genetic and smoking behavior risk main and interaction
effects on predicting high blood pressure among African Americans.

Results

Descriptive statistics of both the HyperGEN and GENOA samples can be found in table 1. We tested the association
of the covariates with adjusted SBP and DBP in a full model including age, age2, sex, BMI, current Smoking and top
ten principal components from the GWAS data (full model summarized in table 2). Age was consistently associated
with both adjusted SBP and DBP. BMI and current smoking status were significantly associated with SBP but not
DBP in the HyperGEN sample. Age2 and sex were only significantly associated with DBP in this African American
sample. Three out of the top ten principal components were significantly associated with adjusted SBP and DBP.
We conducted the joint analysis of the main SNP effect and the SNP ×  Smoking interaction of 761,050 SNPs
in 1,083 African American participants of HyperGEN. We identified fourteen SNPs having significant joint
association with SBP using a threshold of false discovery rate (FDR) q-value less than 0.1 (Table 3). Using a
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Adjusted SBP
Variables

Adjusted DBP

Beta coefficient

SE

P-value

Beta coefficient

SE

Age

1.75

0.320

<  0.001

2.11

0.173

P-value
<  0.001

Age2

− 6.87 ×  10−3

3.53 ×  10−3

0.051

− 1.76 ×  10−2

1.91 ×  10−3

<  0.001

Sex

− 1.93

1.57

0.218

− 2.44

0.842

0.004

BMI

0.662

9.32 ×  10−2

<  0.001

− 1.35 ×  10− 2

5.04 ×  10− 2

0.788

Current Smoking

5.73

1.65

<  0.001

1.66

0.889

0.062

PC1

35.6

26.5

0.181

30.2

14.8

0.042

PC2

− 43.0

33.2

0.196

− 9.04

19.5

0.644

PC3

69.2

29.3

0.019

28.1

16.8

0.094

PC4

− 29.3

30.8

0.342

− 3.74

17.9

0.835

PC5

− 6.78

29.5

0.819

− 8.15

16.9

0.630

PC6

− 27.3

31.1

0.380

− 2.43

18.1

0.893

PC7

23.0

32.8

0.484

31.6

19.2

0.099

PC8

− 65.4

32.0

0.041

− 38.1

18.6

0.041

PC9

1.78 ×  10−2

31.0

1.00

24.9

18.0

0.166

PC10

− 72.7

29.9

0.015

− 49.7

17.2

0.004

Table 2. The associations of covariates and systolic and diastolic blood pressure.

more conservative Bonferroni correction of multiple testing (nominal p-value of 6.57 ×  10−8 of 761,050 SNPs),
we identified two SNPs located on chromosome 14 (rs11158609) and 17 (rs8078051) significantly associated
with SBP including the genetic interaction with cigarette smoking. SNP rs11158609 (p-value of 9.80 ×  10−9,
genomic control-adjusted p =  2.09 ×  10−7) is located in the intronic region of neural precursor cell expressed,
developmentally down-regulated 8 (NEDD8). SNP rs8078051 (p-value of 6.28 ×  10−8, genomic control-adjusted
p =  9.65 ×  10−7) is also located in the intronic region of gene tweety homolog 2 Drosophila (TTYH2). The QQ-plots
(Fig. 1) of the p-values from the joint analysis suggested a moderate inflation of the genome-wide analysis. The
inflation factors were 1.22 and 1.16 for SBP and DBP correspondingly, based on the method of genomic control23.
After applying genomic control, the adjusted p-values of the most significant SNPs rs11158609 and rs8078051 were
2.09 ×  10−7 and 9.65 ×  10−7 (Table 3), which were no longer genome-wide significant. The p-values of the main SNP
effects (without the interaction term in the model) of rs11158609 and rs8078051 are 3.95 ×  10−5 and 4.19 ×  10−3
respectively. The p-values of SNP ×  Smoking term (1df test) are summarized in Supplementary table 1. For DBP,
we did not identify any significant joint association including both main genetic effect and the SNP ×  Smoking
interaction after correction for multiple testing. SNP rs11213629 with the lowest p-value (5.99 ×  10−7) is located
in an intergenic region on chromosome 11.
We examined the impact of alternative BP adjustment methods for antihypertensive use on the 2df
SNP ×  Smoking interaction analysis in HyperGEN African Americans. In Supplementary table 2, we summarize the
p-values of the top associations from three adjustment methods for antihypertensive use: 1) add category-specific
mean to SBP/DBP; 2) add 10/5 mmHg to SBP/DBP; 3) add 15/10 mmHg to SBP/DBP for patients taking antihypertensive medications. The most significant associations from method 1 also show similar low p-values using
method 2 and 3. Among fourteen top associations, method 1 provides the lowest p-values in thirteen SNPs. For
instance, rs11158609 and rs8078051, the two most significant SNPs using method 1, have p-values of 1.08 ×  10−6
and 4.71 ×  10−7 using method 2, and 6.09 ×  10−7 and 5.17 ×  10−7 using method 3.
Using 1,427 African American participants from the GENOA study, we did not replicate the fourteen top associations (FDR less than 0.1 in HyperGEN) with SBP or DBP by testing the joint effects of SNP and SNP ×  Smoking
interaction, at the alpha level of 0.05 (Table 3). However, the joint association between rs11158609 and SBP
remained significant (p-value of 2.98 ×  10−8) in the combined test of HyperGEN and GENOA African American
samples. Further illustration of these findings can be found in Figs 2,3 (Manhattan Plots of joint SNP ×  Smoking
interaction associated with SBP and DBP).
We conducted additional tests for hypertension to compare the association results with SBP for the most significant SNPs.We further examined the association with hypertension status using the generalized estimating equation
(GEE) models to adjust for the familial relatedness. Using the likelihood ratio test to compare the full model with
SNP and SNPxSmoking interaction terms and the reduced model without these two terms, we examined the joint
effects of top two SNPs, rs11158609 and rs8078051. In both cases, the SNP terms improve the fitting with p-values
of 0.12 and 0.0078 for rs11158609 and rs8078051 respectively, which is consistent with the association with SBP
with less degree of significance.

Discussion

The two most significant loci associated with SBP are located in two known genes, NEDD8 and TTYH2 respectively.
Interestingly, the protein products of NEDD8 and TTYH2 were both predicted to bind with neural precursor cell
expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase (NEDD4L) with moderate confidence scores of 0.589 (TTYH2) and 0.281 (NEDD8) using Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING) 9.024, an online database of known and predicated protein-protein interaction. Although
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Chr

Position
(GRCh37/hg19)

Band

Allele#

MAF

Closest Gene

Location

HyperGEN
P-value

HyperGEN
PGC

HyperGEN
FDR

GENOA
P-value

Combined
P-value

rs11158609

14

24688814

q12

G/A

0.079

NEDD8

intronic

9.80 ×  10−9

2.09 ×  10−7

0.007

0.142

2.98 ×  10−8

rs8078051

17

72251240

q25.1

G/A

0.142

TTYH2

intronic

6.28 ×  10

−8

9.65 ×  10

0.024

0.770

8.63 ×  10−7

rs3817779

6

166905534

q27

T/C

0.136

RPS6KA2

intronic

2.42 ×  10

−7

−6

2.94 ×  10

0.059

NA

NA

rs11726022

4

188170467

q35.2

G/A

0.149

LOC339975*

intergenic

3.14 ×  10−7

3.64 ×  10−6

0.059

0.381

2.03 ×  10−6

rs1596724

4

32555853

p15.1

T/C

0.107

LOC102723828*

intergenic

4.06 ×  10−7

4.50 ×  10−6

0.061

0.170

1.21 ×  10−6

rs1792738

18

53845164

q21.31

G/A

0.091

LINC01539*

intergenic

4.93 ×  10−7

5.29 ×  10−6

0.062

0.361

2.94 ×  10−6

rs8065772

17

64842925

q24.2

T/C

0.126

CACNG5

intronic

6.44 ×  10−7

6.59 ×  10−6

0.063

0.136

1.51 ×  10−6

rs1157477

18

73850510

q23

G/A

0.200

LOC339298

intronic

6.66 ×  10−7

6.78 ×  10−6

0.063

0.315

3.43 ×  10−6

rs4906269

14

103362017

q32.32

C/A

0.389

TRAF3

intronic

7.53 ×  10−7

7.50 ×  10−6

0.063

NA

NA

rs1862746

16

60462358

q21

C/A

0.413

LOC729159*

intergenic

1.16 ×  10−6

1.07 ×  10−5

0.088

0.201

3.80 ×  10−6

rs1862745

16

60462336

q21

T/C

0.416

LOC729159*

intergenic

1.29 ×  10−6

1.17 ×  10−5

0.089

0.429

8.52 ×  10−6

rs1012264

2

208115003

q33.3

G/A

0.346

LOC101927865

intronic

1.50 ×  10

−6

1.33 ×  10

0.093

0.914

1.99 ×  10−5

rs1028885

6

25434518

p22.2

G/A

0.421

LRRC16A

intronic

1.64 ×  10

−6

1.43 ×  10

0.093

0.530

1.30 ×  10−5

rs639709

5

103311439

q21.2

G/C

0.153

NUDT12*

intergenic

1.72 ×  10

−6

1.48 ×  10

0.093

0.976

2.40 ×  10−5

SNP

−7

−5
−5
−5

Table 3. Joint Association (2df) of SNP main effect and SNP × Smoking interaction with SBP with FDR
q-value less than 0.1. PGC: P-values adjusted for genome-wide inflation using genomic control (GC). #the first
allele is the effect allele, and the second allele is the reference allele. *the closest gene within 1 Mbp flanking
region of the SNP.

Figure 1. 2 × 2 QQ Plot.
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Figure 2. Systolic Blood Pressure (SBP) Manhattan Plot.

Figure 3. Diastolic Blood Pressure (DBP) Manhattan Plot.
cigarette smoking is a major risk factor for hypertension, it is also widely accepted as a risk factor for cancer,
therefore, we will discuss the genetic links with both hypertension and briefly with cancer.

TTHY2. Tweety proteins are a family of chloride ion channels located extracellularly with the carboxyl-terminal
domain located cytoplasmically25–26and in humans is thought to function as a volume-regulated chloride channel25,27–29. Reference alleles are G/A, the ancestral allele being G, and MAF is 0.0429. Located at 17q24, the population genetics for African Americans for the G allele is 84% and for the A allele is 16%28. NEDD4-2 (NEDD4L) was
found to mediate ubiquitination of the tweety family members, in particular ion channels25. This is significant in
that TTHY2 may function in addition to ion channel activity within mediating cell-to-cell interactions by binding to integrins. NEDD4L gene encodes a member of the NEDD4 family of HECT domain E3 ubiquitin ligases,
which target specific proteins for lysosomal degradation. The NEDD4L protein mediates the ubiquitination of
multiple target substrates and plays a critical role in epithelial sodium transport by regulating the expression
of the epithelial sodium channel. SNP in NEDD4L is suggested to be associated with essential hypertension30.
Genetic association studies have identified that NEDD4L variants were associated with blood pressure response
to diuretics31–33. In addition, a SNP close to NEDD4L is strongly associated with the serum level of a liver enzyme,
gamma-glutamyl transferase (p-value of 3 ×  10−12) in a GWAS34. In other genomic studies, NEDD4L has also
been shown to be associated with hypertension35, obesity36, smoking and cancer37 among a homogeneous population of Chinese Kazakh herders. Although these informative studies shed light on the associations of NEDD4L
and hypertension and smoking independently, our study expands this work by examining and the independent
and interactive effects of genetics and smoking on blood pressure among an African American population.
NEDD8.

NEDD8, also known as neddylin, a ubiquitin-like protein that functions in cell cycle control and
embryogenesis. NEDD8 is highly expressed in heart, skeletal muscle, spleen, thymus, prostate, testis, ovary, colon,
and in leukocytes38–42. NEDD8 gene is located on chromosome 14 position 24688814, with SNP alleles A/G, the
ancestral allele being A, and MAF is 0.108. The NEDD8 pathway has been shown to play an important part in
regulating the actin cytoskeleton and cellular morphology43.
Specifically in strokes, after toxic levels of ischemia, an accumulation of ubiquitinated proteins have been found
in damaged brain regions, while under conditions of mild or reversible ischemia, the ubiquitinated proteins have
been shown to play a protective role44–47. In patients with antiphospholipid syndrome, an acquired autoimmune
Scientific Reports | 6:18812 | DOI: 10.1038/srep18812
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disorder of arterial or venous thrombosis and/or pregnancy morbidity in the presence of antiphopholipid antibodies, their was the presence of proteins NEDD8, RhoA, Hsp60, annexin I-II, and protein disulfide isomerase
which are all related to procoagulant states46. While this research including a number of genes and proteins is still
relatively new, the proteasome may be involved in gene expression, transcription, cell cycle regulation, apoptosis,
and the inflammatory process involving a number of disease processes such as hypertension41,48.

Approach and Comparison with Previous Findings.

Our analysis approach does not test a “perfect”
or “pure” smoking-SNP interaction. Several statistical methods have been developed to assess gene-environment
interactions on a genome-wide scale7. Our primary goal here is to identify genetic loci associated with blood pressure traits considering the interaction effects. This approach can potentially improve power by combining both
marginal and interaction effects with limited sample size10. Because this is a genetic association study of African
Americans, we examined the SBP-associated SNPs reported from the COGENT (African Ancestry) blood pressure GWAS in our cohort22. Both HyperGEN and GENOA contributed to the COGENT BP GWAS study. There
are two SNPs associated with SBP with p-value less than 10−6, rs11041530 (CYB5R2) with p-value of 4.0 ×  10−8
and rs17428471 (EVX1-HOXA) with p-value of 4.0 ×  10−7. Although the SNP main effects of rs11041530 are similar (− 1.67 in HyperGEN and -1.35 in COGENT), the association is not significant (p-value of 0.28) and may be
due to limited sample size. Using the SNAP database49, we did not identify any proxy SNPs of rs17428471 on the
Affymetrix 6.0 array with R2 >  0.8 in YRI. For the top two associations from the joint test, rs11158609 (NEDD8)
and rs8078051 (TTYH2), we looked up their main genetic effects in the COGENT BP meta-analysis22. Neither
SNPs were significantly associated with SBP nor DBP (p-value >  0.05) with inconsistent direction of additive
genetic effects across nineteen participating cohorts.

Limitations. Some limitations of the present study need to be considered. The top two SNPs have unusually
large effect size. The joint SNP and SNP ×  Smoking interaction effects explain about 3% of variance (i.e. R2) of
SBP based on the partial F-test. In previous GWAS of blood pressure readings, the identified SNP associations
have much smaller effect sizes. For example, the top 29 blood pressure-associated SNPs identified by the ICBP
collectively explains only 0.9% of the phenotypic variance for SBP20. Assuming effect size of 2% R2 for the joint
test, we have 22% power using the current AA sample, and only 1.6% power for detecting joint effect size of 1%
R2. Thus, having larger sample size of consistently phenotyped AAs will be critical for discovering BP-associated
SNPs and genes in the future, in addition to the implementation of complementary statistical approaches.
The approach was based on the premise that susceptibility alleles for common diseases were not under strong
negative selection, and common variants contributed to common disease traits (i.e. the ‘common disease-common
variant’ hypothesis)50. However, the allelic spectrum for genes associated with complex quantitative traits, such
as BP, was not fully delineated. It was possible that multiple rare polymorphisms in the biological and positional
candidate genes that were studied could influence BP. Due to a lack of statistical power, identifying associations
with BP using such alleles would not be possible using approaches employed in this study. The inferences may not
be generalizable to individuals who are younger, normotensive, or of other ethnic groups. The validation of the
Dinamap sphygmomanometers used in the HyperGEN study to collect blood pressure readings has been accepted
for clinical investigation worldwide. In terms of GENOA, the use of random-zero sphygmomanometers for measuring blood pressure have been validated for many years. Despite some limitations, the approach employed in the
present study illustrated the use of SNPs in candidate genes to construct a more complete picture of the genetic
architecture of complex traits, such as BP.
Genomic control (GC) is an effective tool to control for type I error in GWAS. However, it tends to over-correct
the most significant results and reduces power (i.e. increase type II error). Therefore, we presented both the unadjusted and GC-adjusted results to balance the strength and limitation of GC. To account for population stratification, we adjusted for the top 10 PCs in all regression models. No inflation was observed in the genome-wide SNP
association analysis. Thus, the observed inflation is unlikely due to population stratification.
We observed modest inflation of low p-values (inflation factor of 1.22 and 1.16 for SBP and DBP respectively)
from the 2df joint test for SNP ×  Smoking interaction (Fig. 1A,B). The p-values are less significant after control for
the inflation (Fig. 1C,D). Furthermore, we recognize that replication is important for validation of genetic effects.
Insufficient sample sizes (full sample and re-sampled subsets) or random measurement error may have limited
the power to detect the effects of SNP ×  Smoking interaction. Additional replication with independent African
American cohorts with similar characteristics are necessary to further validate the findings.
Genome-wide association is a favored approach for genetic studies of common human diseases. However,
localizing and identifying genes underlying environmental variations and the occurrence of high blood pressure
poses a formidable challenge. The next step in studying African Americans and high blood pressure could use a
similar research design incorporating a genome-wide association and other approaches in studying gene-cigarette
smoking interactions on high blood pressure.

Conclusions

Many of the genetic studies utilizing data to uncover genes or proteins responsible for underlying disease states
utilize genome wide association studies with multivariate analysis and pairwise combinations of traits, specifically
addressing genes that serve in a pleiotropic role51. This enables phenotype and genotype information to be reflected
in correlation to a combination of traits. This is a useful approach in that many unique variants within a number of
genes can be studied in association with disease traits. Though many genetic determinants have been found significantly associated with hypertension52,53 and/or metabolic syndrome for instance54, further research is indicated
to understand the protein-gene interaction, methylation patterns, and signaling pathways, which if studied could
provide novel approaches to pharmacologic care, genetic testing, and to combating disease. TTYH2 and NEDD8
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may play a role in the genetic architecture of cardiovascular disease, blood pressure regulation, and other disorders.
Further research is indicated for a better understanding of how these genes play a role in expression of hypertension.

Methods

The parent study, the GENOA and HyperGEN both had HIC/IRB approval via University of Mississippi Medical
Center, University of Michigan and Washington University in St Louis and the methods were carried out in
accordance with the approved guidelines. Each study performed its own quality control procedures centrally, and
shared the cleaned genotypic data for GWAS analysis. Therefore, the SNP inclusion/exclusion criteria between the
HyperGEN and GENOA studies are not completely identical and details of both are provided.

Study Sample—HyperGEN

Genetic data for HyperGEN were completed utilizing the Affymetrix Genome-Wide Human SNP Arrays.
Subjects with a call rate below 95% or with a sex mismatch were excluded. In HyperGEN, the majority of African
Americans were genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0. We removed samples with
sex-mismatch and pedigree errors. We also removed monomorphic SNPs and SNPs with missing rate > 5% or
Hardy-Weinberg p-value <  10−6, and removed any genotypes with a non-Mendelian pattern of inheritance21–22,55.
The final dataset for the GWAS analysis of blood pressure includes 761,050 SNPs in 1,083 African American participants. (See Table 1 for HyperGen demographics).

The Genetic Epidemiology Network of Arteriopathy (GENOA). Participants in GENOA who
self-reported their ethnicity as African-American were included in the analyses for the present study. Participant
samples were genotyped for 906,602 SNPs using the Affymetrix Genome-Wide Human SNP Array 6.0 platform.
Participants were excluded if they had an overall SNP call rate < 95% or sex mismatch between genotypic and
phenotypic measurement. SNPs were excluded if they had unknown chromosomal location, a call rate less than
95% or a minor allele frequency (MAF) less than 0.05. After quality control filters, 650,367 SNPs were available for
analysis in 1,427 GENOA African American participants who had both genotype and phenotype data.

®

Phenotype Measurement.

A clinical visit was performed and each subject was interviewed by study
personnel for data collection for all variables under study. Blood pressure was obtained using digitized blood
pressure sphygmomanometers and was collected in accordance with JNC-7 guidelines. In the analyses, we corrected for anithypertension medications among the HyperGEN participants in accordance with designations
outlined by HyperGEN investigators which can be found in full detail in Wu et al. 200556. To compare the impact
of various adjustment methods of antihypertensive use on SNP ×  Smoking interaction analysis, we conducted
sensitivity analysis of two alternative BP adjustment methods by adding 10/5 mmHg (CHARGE BP GWAS)15
or 15/10 mmHg (GlobalBPGen GWAS)16 to SBP/DBP for subjects taking antihypertensive medications in
HyperGEN African Americans. There are 56.8% HyperGEN participants taking antihypertensive medication.
For GENOA participants taking antihypertensive medication, we corrected SBP and DBP values by adding
10 and 5 mmHg correspondingly57–58. There are 63.1% GENOA participants taking antihypertensive medication.
The operational definition for hypertension in the GENOA study was described as SBP ≥  140 or DBP ≥ 90 mm
Hg or antihypertension drug prescription at the clinical assessment interview22. Height and weight were measured
using standard clinical methods and body mass index (BMI) was calculated using CDC guidelines for adults55,59.
In the GENOA study, the status of cigarette smoking was collected from a self-reported questionnaire as
“smoked within the past year”, “not smoked within the past year”, “never smoked”. The variable “current smoker”
was defined as an individual who smoked within the past year60. For HyperGEN, cigarette smoking was measured
similarly, with participants being asked if they “ever smoked cigarettes” or if they “smoke cigarettes now” to indicate
if they were current smokers and (for current smokers and past smokers) “Number of cigarettes smoked per day”55.
Age, sex and other phenotypic data were collected from the physical examination and laboratory assessment
at the time of the Phase I study visit in GENOA. The GENOA and HyperGEN studies were approved by the
Institutional Review Boards of all participating institutions: University of Mississippi Medical Center, University
of Michigan and Washington University in St Louis. Each participant gave written informed consent.

Statistical Analysis

We used linear mixed models61 to test for association between each SNP and the medication-adjusted phenotypes (SBP/DBP) in order to account for family structure within HyperGEN (siblings) and GENOA. Each SNP
was tested for additive effects in association with the outcome of interest in a test with one degree of freedom.
We also tested the SNP× smoking interaction effects of medication-adjusted SBP and DBP using multivariable
linear mixed models with age, age2, BMI and top 10 principal components (PCs) of the GWAS data, as covariates. For participants who were taking antihypertensive medication we corrected the observed SBP and DBP
values by adding the mean effect of each of the six major antihypertensive medication categories which include:
angiotensin-converting enzyme (ACE) inhibitors, alpha1-blockers, cardioselective beta-blockers (beta1-blockers),
calcium channel blockers, thiazide and thiazide-like diuretics, and loop diuretics. Data management, descriptive
statistics for the covariates and outcome variables, and the regression analyses were conducted using the statistics
software package R in version 2.11.1 (http://www.r-project.org/).
Several methods to study Gene ×  Environment (G ×  E) interactions are available. In this study, we applied the
joint analysis approach9 to identify genetic variants associated with BPs considering the interaction between SNP
and cigarette smoking. This approach can examine both the main genetic effect and the G ×  E interactions in a
single analysis10. We implemented this approach in our study using the following regression models.
Y i = β 0 + β1Ζi + β 2Smoking i + β 3SN Pi + β 4SN Pi ⁎Smoking i + ei
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Where Yi is the BP outcome (e.g. SBP and DBP) for person i, Zi is a vector of adjustment variables including age,
age2, sex, BMI and the first 10 PCs of the common genome-wide SNPs, Smokingi is the smoking status of person i,
and SNPi is the additive genetic effect of a SNP. β4 represents the effect of SNP ×  Smoking interaction.
Y i = β 0 + β1Ζi + β 2Smoking i + ei

(2)

The full model (1) included SNP, smoking and SNP ×  Smoking terms, and the reduced model (2) only included
smoking. We used a 2 degree-of-freedom (df) partial F-test to examine the null hypothesis H0: beta SNP =  beta
SNP× Smoking =  0. This joint test of SNP main effect and SNP ×  Smoking interaction allowed for screening the
genetic effect conditioning on smoking, and the SNP ×  Smoking interaction effect simultaneously. In the discovery stage, we examined 761,050 SNPs (after quality control) in 1,083 HyperGEN African American participants.
In HyperGEN African Americans, to test the main SNP effect as a comparison, we conducted the standard
GWAS of the same SNPs using model (3), which did not include the interaction term as in model (1). In all genetic
analyses, appropriate methods will be used to account for multiple testing (see details below).
Y i = β 0 + β1Ζi + β 2Smoking i + β 3SN Pi + ei

(3)

Using 1,427 African Americans from GENOA study measured by Affymetrix 6.0 array, we examined the most
significant joint associations of SNP and cigarette smoking with adjusted SBP and DBP to replicate the findings in
HyperGEN African Americans. After applying the same static tests by contracting model (1) and (2), we combined
m
the p-values of the same SNP from the two samples using Fisher’s product method: χ22m = − 2 × Σ ln (pi )where
i=1
m is the number of p-values, pi is the p-value of the ith hypothesis test, and the chi-square distribution has 2m
degrees-of-freedom, under the null hypothesis.
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